SR One
SR One is the corporate venture capital arm of GlaxoSmithKline.
Business Model:
Revenue: $11.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed SR One Information
Geographic Data
Address: 1 Broadway
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$500M
Social
Linkedin
Crunchbase
Metrics
3,468,928Website Global Rank
4,128Website Monthly Traffic
Twitter Followers
Description
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Contact Phone:
+16105671000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2009 | Genocea Biosciences | Series A | 23M |
| 7/2007 | CalciMedica | Series A | 1.5M |
| 10/2015 | Puridify | Series A | 3.4M |
| 3/2003 | Alere | Venture Round | 5.1M |
| 11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 10/2016 | Bicycle Therapeutics | Series A | - |
| 2/2002 | Nucleonics | Series A | 1.6M |
| 11/1999 | Physician Verification Services | Venture Round | - |
| 4/2016 | Second Genome | Series B | 51M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 12/2009 | CalciMedica | Series C | 12M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2002 | Gryphon Therapeutics | Series B | 26M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 10/2015 | Decibel Therapeutics | Series A | 52M |
| 10/2019 | MiroBio | Series A | 33.2M |
| 1/2021 | River 2 Renal | Series A | 40M |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 12/2014 | Avhana Health | Seed Round | 0 |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 6/2022 | Ancora Biotech LLC | Series A | 60M |
| 5/2021 | Pulmocide | Series C | 0 |
| 3/2017 | Pulmocide | Series B | 30.4M |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | MiroBio | Series B | 0 |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 5/1999 | Xenogen Corporation | Series D | 11M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 7/2014 | Atox Bio | Series E | 23M |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 6/2015 | Spero Therapeutics | Series A | 0 |
| 1/2012 | Translate Bio | Series A | 20.7M |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 5/2014 | Puridify | Seed Round | 1.4M |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 11/2010 | Syntaxin | Series C | 29M |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2015 | Akamis Bio | Series C | 38.8M |
| 4/2014 | Spero Therapeutics | Series A | 0 |
| 11/2000 | Onyvax | Venture Round | 14.9M |
| 12/2013 | VHSquared | Series A | - |
| 12/1997 | Onyvax | Venture Round | - |
| 5/2006 | Onyvax | Series C | 14.9M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 1/2009 | CalciMedica | Series C | 4M |
| 8/2016 | Tioma Therapeutics | Series A | 86M |
| 11/2003 | Protein Forest | Series A | 19M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 12/2021 | Nomic Bio | Series A | 17M |
| 12/2017 | Atox Bio | Series F | 0 |
| 1/2002 | Melinta Therapeutics | Series A | 22M |
| 5/2018 | Propeller Health | Series D | 20M |
| 1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
| 2/2007 | Locus Pharmaceuticals | Series E | 30.2M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 12/2003 | Linguagen | Series A | 2M |
| 7/2015 | Translate Bio | Series B | 0 |
| 4/2015 | ZappRx | Series A | 14M |
| 4/2011 | F-Star Therapeutics | Venture Round | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 10/2016 | Propeller Health | Series C | 21.5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 1/2008 | POINT Biomedical | Private Equity Round | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 10/2019 | Arcellx | Series B | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 6/2004 | Nucleonics | Series B | 49.2M |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 10/2013 | F-Star Therapeutics | Series A | 0 |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 10/2012 | Thrasos | Series C | 35M |
| 1/2017 | Translate Bio | Series C | 51M |
| 2/2002 | Avantium | Venture Round | 0 |
| 10/2001 | Therion Biologics | Venture Round | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 75M |
| 9/2003 | Therion Biologics | Venture Round | 0 |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2009 | Bird Rock Bio | Series A | 13M |
| 12/2010 | Semprus BioSciences | Series B | 18M |
| 9/2005 | Algeta | Series A | 28.9M |
| 6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
| 3/2015 | Thrasos | Series D | 21M |
| 5/2000 | Xenogen Corporation | Series E | 30.6M |
| 10/2006 | Morphotek | Series D | 0 |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 12/2012 | River Vision Development | Series A | 17M |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 1/2014 | ZappRx | Seed Round | 1M |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 12/2005 | Hypnion | Series B | 0 |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 8/2021 | ARS Pharmaceuticals | Series D | 55M |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 7/2011 | HTG Molecular Diagnostics | Series D | 0 |
| 5/2010 | Ntprx | Series B | 43M |
| 11/2010 | iPierian | Series B | 29M |
| 7/2016 | Progyny | Series B | 14.7M |
| 5/2017 | Progyny | Series B | 10M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 11/2022 | Rezo | Series A | 0 |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 12/2022 | Pulmocide | Series C | 0 |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 4/2010 | Bicycle Therapeutics | Seed Round | - |
| 1/2021 | River 3 Renal | Series A | 40M |
| 11/2006 | PharmaKodex | Series A | 13.5M |
| 8/1998 | MicroMass Communications | Venture Round | 7M |
| 7/2008 | NuPathe | Series B | 30M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2009 | Anaphore | Series A | 13M |
| 6/2016 | Morphic Therapeutic | Series A | 0 |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 8/2006 | Ablynx | Series C | 50M |
| 4/2017 | ZappRx | Series B | 25M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 10/2010 | Dicerna Pharmaceuticals | Series B | 4M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 1/2015 | Nkarta Therapeutics | Series A | 11M |
| 7/2012 | Akamis Bio | Series B | 34.1M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 6/2022 | MiroBio | Series B | 0 |
| 6/2022 | Ancora Biotech LLC | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 12/2021 | nplex biosciences | Series A | 0 |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 0 |
| 8/2021 | ARS Pharmaceuticals | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
